ABVX
ABIVAX Société Anonyme
Price Chart
Latest Quote
$101.53
-3.40 (-3.24%)
Current Price
| Previous Close | $104.93 |
| Open | $105.31 |
| Day High | $108.16 |
| Day Low | $98.23 |
| Volume | 2,616,754 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 79.69M |
| Total Debt | $39.44M |
| Cash Equivalents | $566.63M |
| Revenue | $5.67M |
| Net Income | $-382.94M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.09B |
| EPS (TTM) | $-5.35 |
| Exchange | NGM |
📊 Comprehensive Analysis
Company Data
| Enterprise Value | $7.86B |
| Sales | $5.67M |
| Income | $-382.94M |
| Book/sh | $6.30 |
| Cash/sh | $6.17 |
| Employees | 80 |
Financial Ratios
| Quick Ratio | 8.07 |
| Current Ratio | 8.25 |
| Debt/Eq | 7.96 |
Returns & Margins
| ROA | -44.65% |
| ROE | -157.07% |
| Gross Margin | 100.00% |
| Operating Margin | -4183.70% |
Ownership
| Institutional Ownership | 70.58% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -35.10 |
| P/S | 1644.59 |
| P/B | 16.10 |
Analyst Data
| Recommendation | buy |
| Target Price | $149.09 |
Technical Indicators
| SMA20 | $116.70 |
| SMA50 | $116.70 |
| SMA200 | $110.03 |
| RSI | 44.61 |
| ATR | 11.8911 |
| Shares Float | 58.23M |
| Short Float | 3.15% |
| Short Ratio | 2.91 |
| Volatility | -0.20 |
| Rel Volume | 0.95 |
Performance History
| Week | -23.45% |
| Month | -19.76% |
| Quarter | -7.13% |
| 6 Months | -8.47% |
| YTD | -24.10% |
| Year | +1159.68% |
| 10 Years | +1123.25% |
Stock Score:
⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature
Sign up for free to view detailed scoring breakdown — premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $101.53 | 2,617,469 |
| 2026-06-04 | $104.93 | 5,267,500 |
| 2026-06-03 | $90.15 | 7,165,700 |
| 2026-06-02 | $72.50 | 16,115,600 |
| 2026-06-01 | $129.69 | 8,092,800 |
| 2026-05-29 | $132.63 | 1,884,100 |
| 2026-05-28 | $129.50 | 1,165,900 |
| 2026-05-27 | $129.73 | 1,081,800 |
| 2026-05-26 | $126.41 | 1,243,300 |
| 2026-05-22 | $121.99 | 1,172,500 |
| 2026-05-21 | $124.03 | 1,667,400 |
| 2026-05-20 | $119.90 | 1,242,500 |
| 2026-05-19 | $113.73 | 1,102,800 |
| 2026-05-18 | $113.55 | 798,100 |
| 2026-05-15 | $114.53 | 943,500 |
| 2026-05-14 | $121.00 | 692,100 |
| 2026-05-13 | $121.91 | 732,300 |
| 2026-05-12 | $121.39 | 734,500 |
| 2026-05-11 | $122.13 | 677,800 |
| 2026-05-08 | $122.74 | 917,600 |
| 2026-05-07 | $124.65 | 1,181,200 |
| 2026-05-06 | $126.54 | 1,240,100 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
📰 Latest News
High Growth Tech Stocks To Watch In The Global Market
Simply Wall St. • 2026-06-05T09:42:03Z
Abivax (ABVX) Jumps 16% on Bargain-Hunting
Insider Monkey • 2026-06-05T01:30:29Z
European shares rise as oil slips, investors watch Middle East
Reuters • 2026-06-04T16:36:54Z
Abivax (ABVX) Skyrockets 24% After Steep Fall
Insider Monkey • 2026-06-04T02:54:58Z
This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?
Motley Fool • 2026-06-03T21:35:00Z
Assessing Abivax (ENXTPA:ABVX) Valuation After Phase 3 Obefazimod Data And Safety Concerns
Simply Wall St. • 2026-06-03T21:17:43Z
Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks • 2026-06-03T13:35:03Z
ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears
Stocktwits • 2026-06-03T00:01:57Z
Abivax Hits 'Best-Case' Scenario For Ulcerative Colitis Drug; So, Why Did Shares Plummet?
Investor's Business Daily • 2026-06-02T20:29:17Z
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires • 2026-06-02T19:45:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | $58,908,708 |
| Cost Of Revenue | - | - | - | $59,186,194 |
| Expenses | ||||
| Interest Expense | $33,207,414 | $14,493,412 | $16,119,855 | $8,091,407 |
| Total Expenses | $286,878,856 | $201,683,568 | $148,509,965 | $59,700,360 |
| Other Income Expense | $-36,972,134 | $3,117,640 | $-12,652,442 | $-4,973,767 |
| Net Non Operating Interest Income Expense | $-61,193,889 | $-6,915,005 | $-11,087,793 | $-6,145,505 |
| Total Other Finance Cost | $34,693,948 | $2,863,472 | $-1,798,997 | $-1,945,902 |
| Interest Expense Non Operating | $33,207,414 | $14,493,412 | $16,119,855 | $8,091,407 |
| Operating Expense | $286,878,856 | $201,683,568 | $148,509,965 | $59,700,360 |
| Other Operating Expenses | $-5,328,203 | $-14,513,233 | $-5,387,665 | $-5,343,360 |
| Selling And Marketing Expense | $261,164 | $1,086,627 | $826,629 | $0 |
| General And Administrative Expense | $84,692,781 | $44,267,225 | $32,777,194 | $8,736,155 |
| Other Non Operating Income Expenses | - | $-1,593,797 | $3,728,576 | $1,685,904 |
| Rent Expense Supplemental | - | - | - | $1,221,872 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Net Interest Income | $-61,193,889 | $-6,915,005 | $-11,087,793 | $-6,145,505 |
| Interest Income | $6,707,473 | $10,441,879 | $3,233,065 | $0 |
| Normalized Income | $-364,135,179 | $-208,599,739 | $-159,598,924 | $-65,843,534 |
| Net Income From Continuing And Discontinued Operation | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Total Operating Income As Reported | $-286,878,856 | $-201,683,568 | $-148,508,799 | $-75,592,863 |
| Net Income Common Stockholders | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Net Income | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Net Income Including Noncontrolling Interests | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Net Income Continuous Operations | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Pretax Income | $-385,046,045 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Special Income Charges | $-4,474,758 | $0 | $-3,776,379 | $-15,893,669 |
| Interest Income Non Operating | $6,707,473 | $10,441,879 | $3,233,065 | $0 |
| Operating Income | $-286,878,856 | $-201,683,568 | $-148,509,965 | $-59,700,360 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $82,780 |
| Depreciation And Amortization In Income Statement | - | - | - | $82,780 |
| Depreciation Income Statement | - | - | - | $82,780 |
| Gross Profit | - | - | - | $-59,186,194 |
| Per Share | ||||
| Diluted EPS | - | $-3.24 | $-4.00 | $-3.71 |
| Basic EPS | - | $-3.24 | $-4.00 | $-3.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $-9,243,033 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-313,616,642 | $-192,823,827 | $-142,654,771 | $-57,186,661 |
| Total Unusual Items | $-36,972,134 | $3,117,640 | $-12,652,442 | $-4,973,767 |
| Total Unusual Items Excluding Goodwill | $-36,972,134 | $3,117,640 | $-12,652,442 | $-4,973,767 |
| Reconciled Depreciation | $1,249,854 | $1,282,500 | $824,298 | $565,466 |
| EBITDA (Bullshit earnings) | $-350,588,776 | $-189,706,187 | $-155,307,214 | $-62,160,428 |
| EBIT | $-351,838,630 | $-190,988,686 | $-156,131,511 | $-62,725,893 |
| Diluted NI Availto Com Stockholders | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Tax Provision | $6,818,235 | $0 | $0 | $0 |
| Other Special Charges | $4,474,758 | - | $3,776,379 | $16,171,155 |
| Gain On Sale Of Security | $-32,497,376 | $3,117,640 | $-8,876,064 | $10,919,902 |
| Research And Development | $207,253,114 | $170,842,948 | $120,293,806 | $56,307,565 |
| Selling General And Administration | $84,953,945 | $45,353,852 | $33,603,823 | $8,736,155 |
| Other Gand A | $19,210,679 | $18,900,548 | $15,504,255 | $7,100,385 |
| Salaries And Wages | $65,482,102 | $25,366,678 | $17,272,939 | $1,635,770 |
| Diluted Average Shares | - | $73,857,801 | $50,211,042 | $22,260,046 |
| Basic Average Shares | - | $73,857,801 | $50,211,042 | $22,260,046 |
| Impairment Of Capital Assets | - | $0 | $0 | $15,893,669 |
| Restructuring And Mergern Acquisition | - | $1,593,797 | $-3,728,576 | $-1,685,904 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Other Taxes | - | - | - | $51,300 |
| Rent And Landing Fees | - | - | - | $1,221,872 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $501,551,813 | $18,140,375 | $199,355,248 | $-20,796,315 |
| Total Assets | $681,288,314 | $239,277,131 | $381,324,464 | $88,077,414 |
| Total Non Current Assets | $38,588,084 | $40,291,476 | $47,907,193 | $45,893,668 |
| Other Non Current Assets | $-1,166 | $2,332 | $2,704,908 | $1,207,882 |
| Non Current Prepaid Assets | $6,975,632 | $7,858,225 | $17,565,582 | $13,651,626 |
| Investmentin Financial Assets | $0 | $146,905 | $144,573 | $0 |
| Goodwill And Other Intangible Assets | $29,175,702 | $29,176,868 | $29,174,536 | $29,178,034 |
| Other Intangible Assets | $7,700,828 | $7,701,994 | $7,699,662 | $7,703,159 |
| Current Assets | $642,700,231 | $198,986,821 | $333,417,271 | $42,183,746 |
| Prepaid Assets | $12,085,811 | $12,576,658 | $6,857,876 | $1,066,807 |
| Receivables | $12,236,213 | $18,261,630 | $22,267,692 | $9,695,698 |
| Other Receivables | $500,175 | - | $69,955 | $296,141 |
| Taxes Receivable | $11,736,038 | $18,205,666 | $22,197,738 | $9,399,557 |
| Notes Receivable | $0 | $55,964 | $69,955 | $296,141 |
| Cash Cash Equivalents And Short Term Investments | $618,378,207 | $168,148,533 | $304,292,870 | $31,421,242 |
| Cash And Cash Equivalents | $602,407,588 | $168,148,533 | $293,741,395 | $31,421,242 |
| Cash Equivalents | $557,935,163 | $101,743,031 | $21,108,779 | $31,414,247 |
| Cash Financial | $44,472,425 | $66,405,502 | $272,632,616 | $6,995 |
| Non Current Deferred Assets | - | - | $2,704,908 | $1,209,047 |
| Other Current Assets | - | - | $-1,166 | - |
| Current Deferred Assets | - | - | $6,699,312 | $1,066,807 |
| Non Current Note Receivables | - | - | - | $1,443,395 |
| Inventory | - | - | - | - |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $2,163,927 | $113,514,047 | $67,674,010 | $45,658,155 |
| Long Term Debt And Capital Lease Obligation | $645,913 | $62,483,384 | $31,227,701 | $10,641,250 |
| Current Debt And Capital Lease Obligation | $1,518,013 | $51,030,662 | $36,446,309 | $35,016,905 |
| Long Term Debt | - | $60,814,969 | $31,041,156 | $9,663,052 |
| Current Debt | - | $49,944,035 | $36,004,430 | $34,381,485 |
| Other Current Borrowings | - | $49,944,035 | $36,004,430 | $34,381,485 |
| Net Debt | - | - | - | $12,623,295 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $150,560,799 | $191,959,888 | $152,794,680 | $79,695,696 |
| Total Non Current Liabilities Net Minority Interest | $77,084,060 | $83,723,911 | $50,060,626 | $19,694,531 |
| Other Non Current Liabilities | $35,253,584 | $15,183,630 | $18,064,591 | $7,635,537 |
| Derivative Product Liabilities | $0 | $4,220,590 | $0 | $659,904 |
| Non Current Deferred Liabilities | $6,818,235 | $0 | $0 | - |
| Non Current Deferred Taxes Liabilities | $6,818,235 | $0 | $0 | - |
| Current Liabilities | $73,476,738 | $108,235,978 | $102,734,054 | $60,001,165 |
| Current Deferred Liabilities | $0 | $0 | $60,627 | $155,066 |
| Payables And Accrued Expenses | $52,103,298 | $56,585,052 | $62,135,944 | $20,724,029 |
| Payables | $52,103,298 | $56,585,052 | $62,135,944 | $20,724,029 |
| Total Tax Payable | $8,321,091 | $5,490,265 | $7,080,564 | $2,681,590 |
| Accounts Payable | $43,782,207 | $51,094,787 | $55,055,379 | $18,042,439 |
| Other Current Liabilities | - | - | $4,091,174 | $4,105,165 |
| Other Payable | - | - | $4,306,867 | $1,571,645 |
| Interest Payable | - | - | - | $763,670 |
| Equity | ||||
| Common Stock Equity | $530,727,515 | $47,317,243 | $228,529,784 | $8,381,718 |
| Total Equity Gross Minority Interest | $530,727,515 | $47,317,243 | $228,529,784 | $8,381,718 |
| Stockholders Equity | $530,727,515 | $47,317,243 | $228,529,784 | $8,381,718 |
| Gains Losses Not Affecting Retained Earnings | $2,692,083 | $-87,443 | $130,582 | $0 |
| Retained Earnings | $-861,002,662 | $-511,692,888 | $-329,892,729 | $-167,319,572 |
| Other Equity Interest | - | - | - | $7,950,332 |
| Other | ||||
| Ordinary Shares Number | $91,566,294 | $73,857,801 | $73,356,042 | $26,001,148 |
| Share Issued | $91,566,294 | $73,857,801 | $73,369,263 | $26,001,148 |
| Tangible Book Value | $501,551,813 | $18,140,375 | $199,355,248 | $-20,796,315 |
| Invested Capital | $530,727,515 | $158,076,247 | $295,575,369 | $52,426,255 |
| Working Capital | $569,223,492 | $90,750,843 | $230,683,217 | $-17,817,418 |
| Capital Lease Obligations | $2,163,927 | $2,755,042 | $628,425 | $1,613,618 |
| Total Capitalization | $530,727,515 | $108,132,212 | $259,570,940 | $18,044,770 |
| Foreign Currency Translation Adjustments | $2,692,083 | $-87,443 | $130,582 | $0 |
| Additional Paid In Capital | $1,388,122,856 | $558,359,554 | $557,558,575 | $175,441,293 |
| Capital Stock | $915,238 | $738,020 | $733,357 | $259,998 |
| Common Stock | $915,238 | $738,020 | $733,357 | $259,998 |
| Employee Benefits | $731,025 | $881,427 | $733,357 | $711,204 |
| Non Current Pension And Other Postretirement Benefit Plans | $731,025 | $881,427 | $733,357 | $711,204 |
| Long Term Capital Lease Obligation | $645,913 | $1,668,415 | $186,545 | $978,197 |
| Long Term Provisions | $33,635,303 | $954,879 | $34,977 | $46,636 |
| Current Deferred Revenue | $0 | $0 | $60,627 | $155,066 |
| Current Capital Lease Obligation | $1,518,013 | $1,086,627 | $441,879 | $635,420 |
| Current Provisions | $19,855,427 | $620,263 | - | - |
| Investments And Advances | $0 | $146,905 | $144,573 | $0 |
| Goodwill | $21,474,874 | $21,474,874 | $21,474,874 | $21,474,874 |
| Net PPE | $2,437,915 | $3,107,147 | $1,022,502 | $1,856,127 |
| Accumulated Depreciation | $-2,545,179 | $-1,590,300 | $-1,736,038 | $-942,054 |
| Gross PPE | $4,983,094 | $4,697,447 | $2,758,540 | $2,798,181 |
| Other Properties | $539,816 | $598,111 | $598,111 | $508,336 |
| Machinery Furniture Equipment | $707,707 | $813,804 | $591,116 | $403,404 |
| Buildings And Improvements | $3,735,572 | $3,285,531 | $1,569,313 | $1,886,440 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $15,970,619 | $0 | $10,551,475 | $0 |
| Available For Sale Securities | - | $146,905 | $144,573 | $89,775 |
| Treasury Shares Number | - | - | $13,220 | $13,991 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $1,346,625 |
| Current Accrued Expenses | - | - | - | $763,670 |
| Construction In Progress | - | - | - | $78,116 |
| Work In Process | - | - | - | - |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-188,027,278 | $-180,383,580 | $-113,553,688 | $-63,261,046 |
| Operating Activities | ||||
| Operating Cash Flow | $-187,861,719 | $-179,633,901 | $-113,244,722 | $-62,884,457 |
| Cash Flow From Continuing Operating Activities | $-187,862,885 | $-179,635,067 | $-113,244,722 | $-62,880,959 |
| Operating Gains Losses | $72,595,311 | $1,718,550 | $-1,262,679 | $-12,570,829 |
| Investing Activities | ||||
| Capital Expenditure | $-165,559 | $-749,679 | $-308,966 | $-376,589 |
| Investing Cash Flow | $-9,552,291 | $18,377,055 | $-9,438,032 | $-14,021,219 |
| Cash Flow From Continuing Investing Activities | $-9,552,291 | $18,378,220 | $-9,438,032 | $-14,021,219 |
| Net Other Investing Changes | $-15,834,207 | $9,591,932 | $-11,927,247 | $-10,270,491 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $755,653,475 | $506,004 | $412,017,013 | $54,067,855 |
| Financing Cash Flow | $638,110,048 | $32,886,790 | $390,917,562 | $37,555,088 |
| Cash Flow From Continuing Financing Activities | $638,110,048 | $32,886,790 | $390,916,396 | $37,556,254 |
| Net Other Financing Charges | $-47,352,220 | $-2,351,638 | $-32,711,903 | $-509,502 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $755,653,475 | $506,004 | $412,017,013 | $54,067,855 |
| Common Stock Issuance | $755,653,475 | $506,004 | $412,017,013 | $54,067,855 |
| Other | ||||
| Repayment Of Debt | $-69,410,049 | $-12,193,074 | $-47,338,229 | $-11,322,140 |
| Issuance Of Debt | $0 | $55,898,332 | $65,105,513 | $0 |
| End Cash Position | $602,407,588 | $168,148,533 | $293,741,395 | $31,421,242 |
| Beginning Cash Position | $168,148,533 | $293,741,395 | $31,421,242 | $70,771,830 |
| Effect Of Exchange Rate Changes | $-11,951,731 | $2,777,195 | $-5,913,489 | $0 |
| Changes In Cash | $446,210,786 | $-128,370,057 | $268,233,642 | $-39,350,588 |
| Other Cash Adjustment Inside Changein Cash | $5,514,749 | $0 | $0 | - |
| Interest Paid Cff | $-7,566,748 | $-8,972,834 | $-6,154,833 | $-4,681,124 |
| Proceeds From Stock Option Exercised | $6,785,589 | $0 | $0 | $3,498 |
| Net Issuance Payments Of Debt | $-69,410,049 | $43,705,257 | $17,767,284 | $-11,322,140 |
| Net Long Term Debt Issuance | $-69,410,049 | $43,705,257 | $17,767,284 | $-11,322,140 |
| Long Term Debt Payments | $-69,410,049 | $-12,193,074 | $-47,338,229 | $-11,322,140 |
| Long Term Debt Issuance | $0 | $55,898,332 | $65,105,513 | $0 |
| Interest Received Cfi | $6,447,476 | $9,534,802 | $2,798,181 | $22,152 |
| Net Intangibles Purchase And Sale | $0 | $-3,498 | $0 | $-40,807 |
| Purchase Of Intangibles | $0 | $-3,498 | $0 | $-40,807 |
| Net PPE Purchase And Sale | $-165,559 | $-746,182 | $-308,966 | $-335,782 |
| Purchase Of PPE | $-165,559 | $-746,182 | $-308,966 | $-335,782 |
| Change In Working Capital | $4,257,899 | $1,659,088 | $24,794,217 | $-2,334,149 |
| Change In Other Working Capital | $827,795 | $2,055,497 | $-94,439 | $-30,314 |
| Change In Payables And Accrued Expense | $-4,780,226 | $-5,749,096 | $41,480,703 | $-2,667,599 |
| Change In Payable | $-4,780,226 | $-5,749,096 | $41,480,703 | $-2,667,599 |
| Change In Account Payable | $-7,240,294 | $-4,015,390 | $37,025,766 | $-2,784,190 |
| Change In Tax Payable | $2,460,068 | $-1,733,706 | $4,454,938 | $116,591 |
| Change In Income Tax Payable | $2,460,068 | $-1,733,706 | $4,454,938 | $116,591 |
| Change In Receivables | $8,210,330 | $5,352,687 | $-16,592,048 | $363,764 |
| Other Non Cash Items | $25,688,469 | $-2,391,279 | $25,114,841 | $7,735,805 |
| Stock Based Compensation | $41,269,674 | $23,579,340 | $9,535,968 | $-1,357,118 |
| Provisionand Write Offof Assets | $52,123,119 | $0 | $0 | - |
| Deferred Tax | $6,818,235 | $0 | $0 | - |
| Deferred Income Tax | $6,818,235 | $0 | $0 | - |
| Depreciation Amortization Depletion | $1,249,854 | $1,282,500 | $824,298 | $565,466 |
| Depreciation And Amortization | $1,249,854 | $1,282,500 | $824,298 | $565,466 |
| Pension And Employee Benefit Expense | $-75,784 | $86,277 | $127,084 | $166,725 |
| Gain Loss On Investment Securities | $72,671,096 | $1,632,272 | $-1,389,763 | $-12,737,554 |
| Net Income From Continuing Operations | $-391,864,279 | $-205,482,099 | $-172,251,366 | $-70,817,301 |
| Net Business Purchase And Sale | - | $0 | $0 | $-3,396,292 |
| Purchase Of Business | - | $0 | $0 | $-3,396,292 |
| Asset Impairment Charge | - | $0 | $0 | $15,893,669 |
| Other Cash Adjustment Outside Changein Cash | - | - | $-1,166 | $-3,498 |
| Net Investment Purchase And Sale | - | - | $-10,038,475 | $-547,977 |
| Sale Of Investment | - | - | $863,938 | $254,168 |
| Purchase Of Investment | - | - | $-10,902,413 | $-547,977 |
| Change In Other Current Assets | - | - | $4,360,499 | $-37,309 |
| Amortization Cash Flow | - | - | $0 | $360,266 |
| Amortization Of Intangibles | - | - | $0 | $360,266 |
| Depreciation | - | - | $825,463 | - |
| Net Foreign Currency Exchange Gain Loss | - | - | $6,497,610 | $0 |
| Sale Of PPE | - | - | - | - |
| Taxes Refund Paid | - | - | - | - |
| Interest Received Cfo | - | - | - | - |
| Interest Paid Cfo | - | - | - | - |
| Change In Other Current Liabilities | - | - | - | - |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-05-30